EUVIMEDEUVIMED entdecken
Crossref

A Modular Peptide Strategy for Targeted Lysosomal Degradation of TGF-βR1

Liang Qi, Daimin Luo, Wei Cheng, Qinglin Tang, Jiale Dong, Han Liu, Zhuowen Li, Yanqiu Yuan iD, Haonan Li, Xianxing Jiang iD

Journal of Medicinal Chemistry · 12.11.2026 · 69 (21) · 25510-25531

DOI: 10.1021/acs.jmedchem.6c01441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.10.2026. Verfasst von Liang Qi und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangdong, Guangzho…. Hauptthemen laut MEDLINE: Lysosomes, Peptides, Receptor, Transforming Growth Factor-beta Type I. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Science and Technology Major Project, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Direct depletion of TGF-βR1 may provide more durable suppression of profibrotic signaling than occupancy-driven inhibition, but compact lysosome-directed degraders remain underdeveloped. Here, we report a peptide-based strategy for lysosomal degradation of TGF-βR1 by re-engineering a caveolin-derived antifibrotic scaffold. Structure-guided optimization identified T19 as an improved TGF-βR1-directed sequence, and incorporation of an intrinsic lysosome-targeting module generated P2, which induced time and dose-dependent, lysosome-dependent TGF-βR1 downregulation. Fatty-acid conjugation afforded P2-FA with improved stability and pharmacokinetic properties. P2-FA suppressed profibrotic signaling, reduced α-SMA and COL1A1 expression, and inhibited proliferation and migration of activated LX-2 cells. In a CCl4-induced mouse model, P2-FA attenuated collagen deposition, decreased fibrotic marker expression, and alleviated liver injury. These results identify P2-FA as a pharmacologically improved peptide-based TGF-βR1 degrader and antifibrotic lead.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysosomesPeptidesReceptor, Transforming Growth Factor-beta Type IAnimalsHumansMiceLiver CirrhosisMaleMice, Inbred C57BLCell ProliferationProteolysisSignal Transduction

Stichwörter der Autor:innen

TGF-βR1caveolin-1liver fibrosislysosomal degradation peptides

Substanzen

PeptidesReceptor, Transforming Growth Factor-beta Type I

Autor:innen und Institutionen

  • State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangdong, Guangzhou510006, China.
  • State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou730000, China.

ORCID-Profile: Yanqiu Yuan, Xianxing Jiang

Förderung

  • National Science and Technology Major Project
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Qi, L., Luo, D., Cheng, W., Tang, Q., Dong, J., Liu, H., Li, Z., Yuan, Y., Li, H., & Jiang, X. (2026). A Modular Peptide Strategy for Targeted Lysosomal Degradation of TGF-βR1. Journal of Medicinal Chemistry, 69(21), 25510-25531. https://doi.org/10.1021/acs.jmedchem.6c01441

Vancouver

Qi L, Luo D, Cheng W, Tang Q, Dong J, Liu H, et al. A Modular Peptide Strategy for Targeted Lysosomal Degradation of TGF-βR1. Journal of Medicinal Chemistry. 2026;69(21):25510-25531. doi:10.1021/acs.jmedchem.6c01441

BibTeX
@article{Qi2026,
  author = {Qi, Liang and Luo, Daimin and Cheng, Wei and Tang, Qinglin and Dong, Jiale and Liu, Han and Li, Zhuowen and Yuan, Yanqiu and Li, Haonan and Jiang, Xianxing},
  title = {A Modular Peptide Strategy for Targeted Lysosomal Degradation of TGF-βR1},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {21},
  pages = {25510--25531},
  doi = {10.1021/acs.jmedchem.6c01441}
}
Kostenlos starten →